Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tumor DNA study aims to unlock secrets of drug resistance

NCT ID NCT03347318

Knowledge-focused Sponsor: Fondazione del Piemonte per l'Oncologia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affect drug response. This is an observational study, meaning no new treatment is being tested.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand why some tumors stop responding to targeted drugs, potentially guiding future treatment choices.
What could go wrong
This is an observational study, not a treatment trial. It will not directly benefit participants, and the findings may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2011

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with selected solid tumors (CRC, Prostate Cancer, Head \& Neck Cancer, Gastric Cancer, Glioblastoma, Breast Cancer, Hepatocarcinoma, Biliary Tract Carcinoma, Lung Cancer, Rare Tumors, Metastatic Sarcoma and Metastatic Melanoma).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients with at least one of the following selected solid tumors: * Colorectal Cancer (primary or with synchronous/metachronous liver metastases) * Prostate Cancer * Head \& Neck Tumors * Gastric Cancer * Glioblastoma * Breast Cancer * Hepatocarcinoma * Biliary Tract Carcinoma * Lung Cancer (primary) * Rare Tumors (incidence ≤ 5x10-6) * Metastatic Sarcoma * Metastatic Melanoma Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

biliary tract cancer breast cancer colorectal cancer gastric cancer glioblastoma head and neck cancer hepatocellular carcinoma lung cancer metastatic melanoma prostate cancer sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumors

Contacts and locations

Locations

  • A.O. Città della Salute e della Scienza di Torino - Presidio ospedaliero Ostetrico Ginecologico Sant'Anna

    Turin, Italy

  • AOU Città della Salute e della Scienza di Torino - Presidio Molinette

    Turin, Italy

  • AOU S. Luigi Gonzaga

    Orbassano, Italy

  • Azienda Ospedaliera Niguarda Ca'Granda

    Milan, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy

  • Azienda Ospedaliero-Universitaria Careggi

    Genova, Italy

  • Fondazione IRCCS - Istituto Nazionale dei Tumori

    Milan, Italy

  • IEO - Istiuto Europeo di Oncologia

    Milan, Italy

  • IOV - Istituto Oncologico Veneto

    Padova, Italy

  • Istituto Di Candiolo - Fondazione Del Piemonte Per L'Oncologia (FPO-Irccs)

    Candiolo, Italy

  • Ospedale Mauriziano Umberto I

    Turin, Italy

  • Ospedale Regionale Umberto Parini

    Aosta, Italy

  • Policlinico S.Orsola Malpighi

    Bologna, Italy

  • Policlinico Universitario Campus Biomedico

    Roma, Italy

  • Presidio Ospedaliero Martini

    Turin, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.